Iovance Biotherapeutics
在场
是其中之一......
Iovance Biotherapeutics 是一家在股票代码 IOVA (US) 下上市的公司。
涉及Iovance Biotherapeutics的并购和融资。
- Iovance Biotherapeutics 刚刚宣布为 150 筹款数百万美元。 (公布2023七月13号).
高管
查看带有其 18 名主要高管的组织结构图
Iovance Biotherapeutics 搜索最多的简介
- Frederick Vogt, Director, Interim Chief Executive Officer, Preside...
- Athena Countouriotis, Director
- Iain Dukes, Chairman of the Board
高管在Iovance Biotherapeutics变化
- Raj Puri 曾任 Executive Vice President, Regulatory Strategy and Translational Medicine, 现升职为 Chief Regulatory Officer (新闻发布的2024十一月27号).
- Jim Ziegler, Executive Vice President, Commercial, 已经离开公司 (新闻发布的2024九月11号).
创建提醒
跟踪 Iovance Biotherapeutics 的高管变动
生物技术
Iovance Biotherapeutics 拥有 2,330 家竞争者，其中包括 Eurofins (卢森堡)、Lonza (瑞士) 和 Biogen (美国(美洲))。
Popular M&A news in 生物技术
- Nuvig Therapeutics 刚刚宣布为 161 筹款数百万美元。 (公布2024十二月5号).
- March Biosciences 刚刚宣布为 28 筹款数百万美元。 (公布2024十二月3号).
- Lyell Immunopharma 已收购 ImmPACT Bio (公布2024十一月29号).
生物技术 行业的其他推荐联系人
消息
Iovance Biotherapeutics 的最新新闻稿
- Iovance Biotherapeutics to Host Second Quarter Financial Results Conference Call and Webcast on Thursday, August 4, 2022 | Iovance Biotherapeutics, Inc.
- Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) | Iovance Biotherapeutics, Inc.
- Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) | Iovance Biotherapeutics, Inc.
- Iovance Biotherapeutics Appoints Wendy L. Dixon, Ph.D., to Board of Directors | Iovance Biotherapeutics, Inc.
- Press Releases | Iovance Biotherapeutics, Inc.
- Iovance Biotherapeutics to Present at Upcoming Conferences | Iovance Biotherapeutics, Inc.
- Iovance Biotherapeutics Announces Positive Clinical Data for Lifileucel in Advanced Melanoma | Iovance Biotherapeutics, Inc.
- Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) | Iovance Biotherapeutics, Inc.
- Iovance Biotherapeutics Reports First Quarter 2022 Financial Results and Corporate Updates | Iovance Biotherapeutics, Inc.
- Iovance Biotherapeutics to Present Translational Data for Lifileucel in Advanced Melanoma at 2022 ASCO Annual Meeting | Iovance Biotherapeutics, Inc.
- View more press releases Close
通过电子邮件
